Document is current
Any future updates will be listed below
-
Authors
Kofink, Christiane https://orcid.org/0000-0003-2515-8843
Trainor, Nicole https://orcid.org/0000-0002-3758-9969
Mair, Barbara https://orcid.org/0000-0001-6982-2529
Wöhrle, Simon https://orcid.org/0000-0002-2478-7333
Wurm, Melanie https://orcid.org/0000-0002-2317-6952
Mischerikow, Nikolai
Roy, Michael J. https://orcid.org/0000-0003-0198-9108
Bader, Gerd https://orcid.org/0000-0002-8410-3415
Greb, Peter
Garavel, Géraldine
Diers, Emelyne
McLennan, Ross https://orcid.org/0000-0001-8125-7702
Whitworth, Claire
Vetma, Vesna https://orcid.org/0000-0003-4013-6917
Rumpel, Klaus https://orcid.org/0000-0002-6755-0985
Scharnweber, Maximilian
Fuchs, Julian E. https://orcid.org/0000-0003-4322-9481
Gerstberger, Thomas https://orcid.org/0000-0002-6837-1401
Cui, Yunhai https://orcid.org/0000-0003-4969-072X
Gremel, Gabriela
Chetta, Paolo
Hopf, Stefan https://orcid.org/0000-0001-7930-9526
Budano, Nicole https://orcid.org/0000-0001-8749-0759
Rinnenthal, Joerg
Gmaschitz, Gerhard
Mayer, Moriz
Koegl, Manfred
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Weinstabl, Harald https://orcid.org/0000-0003-1308-2730
Farnaby, William https://orcid.org/0000-0001-8610-932X
- License Information
-
More Information
Article History
Received: 2 March 2022
Accepted: 15 September 2022
First Online: 10 October 2022
Competing interests
: The authors declare the following competing financial interests: The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista therapeutics, Boehringer Ingelheim, Eisai, Merck KGaA, Nurix therapeutics, Ono Pharmaceuticals and Tocris-Bio-Techne. A.C. is a scientific founder, shareholder and consultant of Amphista therapeutics, a company that is developing targeted protein degradation therapeutic platforms. C.K., B.M., S.W., M.W., N.M., G.B., P.G., G.Ga., K.R., M.S., J.E.F., T.G., Y.C., G.Gr., P.C., S.H., N.B., J.R., G.Gm., M.M., M.K. and H.W. are current or former employees of Boehringer Ingelheim. S.W. is now an employee of Merck; E.D. is now an employee of Astra Zeneca. The remaining authors declare no competing interests.
